External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer
2007

Media Influence on Funding for Breast Cancer Treatment

Sample size: 18 publication Evidence: moderate

Author Information

Author(s): Christopher M Booth, George Dranitsaris, Gainford M Corona, Scott Berry, Michael Fralick, John Fralick, Joanna Sue, Mark Clemons

Primary Institution: National Cancer Institute of Canada Clinical Trials Group, Queen's University

Hypothesis

How does media coverage affect the funding decisions for anti-cancer agents like trastuzumab?

Conclusion

Media coverage significantly influences the priority-setting process for funding anti-cancer therapies.

Supporting Evidence

  • 51 episodes of media coverage were identified for trastuzumab during the funding approval period.
  • The median time to funding approval for trastuzumab was 3 months, compared to 31 months for other drugs.
  • Trastuzumab received significantly more media attention than other anti-cancer therapies.

Takeaway

This study shows that when the media talks a lot about a cancer treatment, it can help that treatment get funded faster.

Methodology

A comprehensive search of media coverage related to trastuzumab and other anti-cancer drugs was conducted, analyzing the time to funding approval.

Potential Biases

Potential bias due to the influence of media portrayal on public perception and funding decisions.

Limitations

The study is descriptive and cannot quantify the exact influence of media or other external factors on funding decisions.

Participant Demographics

The study focuses on anti-cancer agents in Ontario, Canada.

Statistical Information

P-Value

0.56

Confidence Interval

95%CI: -.84 to 0.23

Statistical Significance

p = 0.56

Digital Object Identifier (DOI)

10.1186/1471-2407-7-110

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication